Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.71 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.71 |
| ▸ | GLO1 | Q04760 | 3/20 | 0.66 |
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.47 |
| ▸ | FNTA | P49354 | 2/20 | 0.43 |
| ▸ | FNTB | P49356 | 2/20 | 0.43 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| S-Methylglutathione SCHEMBL13157330 | 1.00 | PTGS1 (0.71) | PTGS1GSTK1GLO1NOD1FNTA | |
| S-Methylglutathione SCHEMBL13948109 | 1.00 | PTGS1 (0.71) | PTGS1GSTK1GLO1NOD1FNTA | |
| S-Methylglutathione SCHEMBL1767369 | 1.00 | PTGS1 (0.71) | PTGS1GSTK1GLO1NOD1FNTA | |
| S-Methylglutathione SCHEMBL17997395 | 0.94 | PTGS1 (0.83) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL12773716 | 0.91 | PTGS1 (0.67) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL12829399 | 0.91 | PTGS1 (0.67) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL14066343 | 0.91 | PTGS1 (0.59) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL858838 | 0.91 | PTGS1 (0.59) | PTGS1GSTK1GLO1NOD1FNTA | |
| Oxiglutatione SCHEMBL4362052 | 0.90 | PTGS1 (0.73) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| Oxiglutatione SCHEMBL19579378 | 0.90 | PTGS1 (0.73) | PTGS1GSTK1GLO1NOD1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 241 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12050228-B2 | Automated sample quality assessment | METABOLON, INC. (US) | 2024-07-30 | — | — | US | claimed |
| US-20240240229-A1 | METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2024-07-18 | — | — | US | claimed |
| EP-3270889-B1 | TARGETED LIPOSOMAL DELIVERY OF CGMP ANALOGUES | MIRECA MEDICINES GMBH (DE) | 2024-02-07 | — | — | EP | claimed |
| CN-113552261-B | Marker for identifying ganoderma curvatus and product thereof and application thereof | 中国热带农业科学院环境与植物保护研究所 | 2023-05-02 | — | — | CN | claimed |
| US-20220273791-A1 | SELECTIVE LOCAL INHIBITION OF TNFR1-MEDIATED FUNCTIONS AT THE SITE OF ANTIGEN/ALLERGEN PRESENTATION | BREDEHORST REINHARD (DE) | 2022-09-01 | — | — | US | claimed |
| WO-2022074181-A1 | NANOCARRIER FORMULATIONS FOR INHALATION | EnhanX Biopharm Inc. (TW) | 2022-04-14 | — | — | WO | claimed |
| EP-3395372-B1 | GLUTATHIONE-BASED DRUG DELIVERY SYSTEM | ENHANX BIOPHARM INC (TW) | 2022-04-06 | — | — | EP | claimed |
| US-20210088539-A1 | AUTOMATED SAMPLE QUALITY ASSESSMENT | METABOLON, INC. | 2021-03-25 | — | — | US | claimed |
| US-10890592-B2 | Automated sample quality assessment | METABOLON, INC. (US) | 2021-01-12 | — | — | US | claimed |
| US-20190282692-A1 | SELECTIVE LOCAL INHIBITION OF TNFR1-MEDIATED FUNCTIONS AT THE SITE OF ANTIGEN/ALLERGEN PRESENTATION | BREDEHORST REINHARD (DE) | 2019-09-19 | — | — | US | claimed |
| CN-102316902-A | Glutathione-based drug delivery system | TO BBB HOLDING B V | 2012-01-11 | — | — | CN | claimed |
| EP-2398500-A2 | GLUTATHIONE-BASED DRUG DELIVERY SYSTEM | TO-BBB Holding B.V. (NL) | 2011-12-28 | — | — | EP | claimed |
| US-20110305751-A1 | GLUTATHIONE-BASED DRUG DELIVERY SYSTEM | TO-BBB HOLDING B.V. (NL) | 2011-12-15 | — | — | US | claimed |
| WO-2010095940-A2 | GLUTATHIONE-BASED DRUG DELIVERY SYSTEM | TO-BBB HOLDING B.V. (NL) | 2010-08-26 | — | — | WO | claimed |
| EP-1853292-B1 | PHARMACEUTICAL COMPOSITION COMPRISING GLUTATHIONE COMPOUNDS AND BETALAIN FOR THE PREVENTION AND TREATMENT OF CANCER | GERNOT TREUSCH (ES) | 2008-12-10 | — | — | EP | claimed |
| EP-1853292-A1 | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF CANCER | Gernot, Treusch (ES) | 2007-11-14 | — | — | EP | claimed |
| US-7226766-B2 | S-methylcysteine, S-ethylcysteine, and related S-alkylthiols as antagonists to the effects of S-nitrosothiols and nitric oxide | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2007-06-05 | — | — | US | claimed |
| WO-2006084768-A1 | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF CANCER | GERNOT TREUSCH (ES) | 2006-08-17 | — | — | WO | claimed |
| WO-2002100811-A1 | S-METHYLCYSTEINE S-ETHYLCYSTEINE AND RELATED S-ALKYLTHIOLS AS ANTAGONISTS TO THE EFFECTS OF S-NITROSOTHIOLS AND NITRIC OXIDE | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2002-12-19 | — | — | WO | claimed |
| US-20020187137-A1 | S-methylcysteine, S-ethylcysteine, and related S-alkylthiols as antagonists to the effects of S-nitrosothiols and nitric oxide | UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2002-12-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110305751-A1 | GLUTATHIONE-BASED DRUG DELIVERY SYSTEM | GSS, GSTO1, SLC7A11 | PTGS1 292/4885GSTK1 13/4885GLO1 93/4885 |
| US-20240240229-A1 | METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS | GSTM1, GSTM2, GSTA1 | PTGS1 412/4885GSTK1 7/4885GLO1 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.